Dr Reddy stock gains after semaglutide setback and Q1 FY27 miss

Published on 09/01/2026 at 21:27 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Dr Reddy stock is edging higher as investors digest a provision linked to out-of-specification semaglutide batches and a first-quarter FY27 earnings miss, while the latest live quote shows the shares up over 1 percent on September 1, 2026.

Dr Reddy, INE089A01023, Illustration mit AI erstellt.

Dr Reddy's Laboratories stock (ISIN INE089A01023) was trading around INR 1,171.00 on the National Stock Exchange as of September 1, 2026, up about 1.4 percent from the previous close of INR 1,154.40 according to market data compiled by Upstox.

Price recovery after recent volatility

As of September 1, 2026, live-quote data from The Economic Times showed Dr Reddys last traded price at INR 1,170.0, with an intraday gain of about 1.36 percent and a market capitalization of roughly INR 97,890.78 million.

The same liveblog indicated that the stock had fallen about 8.69 percent over the past six months, highlighting that the current uptick comes after a period of weaker returns for shareholders.

Q1 FY27 miss and semaglutide provision

On July 22, 2026, Dr Reddy's Laboratories reported first-quarter fiscal 2027 results that missed market expectations and booked a provision of INR 2.4 billion related to out-of-specification semaglutide batches, according to a press statement summarized by The National Law Review.

In the accompanying earnings call for Q1 FY27, management explained that the semaglutide quality issue was linked to active pharmaceutical ingredient used in certain batches and emphasized that existing global regulatory filings were unaffected and no patient-safety impact had been identified for product already supplied to the market.

Following the July 22, 2026 disclosure of the Q1 FY27 miss and the INR 2.4 billion provision, Dr Reddy's Laboratories' share price dropped by about 9 percent, illustrating the sensitivity of investors to both earnings surprises and quality-related issues in high-profile products.

Market reaction to semaglutide delay

Recent market commentary compiled by Tickertape noted that Dr Reddy's Laboratories' stock had previously tumbled about 5.24 percent after the company stated that commercial supplies of certain semaglutide batches would be delayed due to the same out-of-specification API issue.

For investors, a key question now is how quickly Dr Reddy can resolve this API-related problem and normalize supplies, as semaglutide belongs to a fast-growing therapeutic segment where reliable quality and delivery are crucial to sustaining revenue growth.

The combination of a Q1 FY27 earnings miss, a sizable INR 2.4 billion provision, and temporary semaglutide supply delays has raised near-term uncertainty, but the modest price recovery seen on September 1, 2026 suggests some investors may be betting that remedial measures will stabilize performance over the coming quarters.

Corporate developments and leadership

Corporate updates highlighted on the same Tickertape overview show that on August 26, 2026 Dr Reddy's Laboratories allotted 4,110 equity shares of nominal value INR 1 each to eligible employees under its 2002 stock option scheme, bringing total issued share capital to INR 8,346,809,10 and total shares to 83,468,0910.

Additionally, Dr Reddy has been strengthening its leadership bench in biologics, appointing a new Global Head of Biologics and Senior Management Personnel effective July 22, 2026, which aligns with the company's strategy to deepen its presence in complex biologics and biosimilars.

Analysts monitoring the stock have noted that quality control and biologics execution will be central to how quickly Dr Reddy can move past the semaglutide-related provision and rebuild investor confidence in its growth trajectory.

Representative product focus: rituximab biosimilar

Among Dr Reddy's key products, a rituximab biosimilar developed and manufactured by the company has received approval from the United States Food and Drug Administration for the U.S. market, with Fresenius Kabi holding exclusive commercialization rights in that territory, as outlined by Tickertape.

This biosimilar positions Dr Reddy in a competitive segment of oncology and autoimmune therapies where originator products are facing patent expiries, and where biosimilars can unlock meaningful revenue and margin opportunities if launched and scaled successfully.

Stock level and investor takeaway

Dr Reddy stock closed around INR 1,170.0 as of September 1, 2026 on Indian exchanges, representing a daily gain of roughly 1.36 percent but still leaving the share price below levels seen before the Q1 FY27 semaglutide-related provision and earnings miss.